Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 9/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | RHOC | P08134 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600617 | 1.00 | HMGCR (1.00) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL5329246 | 0.99 | HMGCR (0.98) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL6362203 | 0.97 | HMGCR (1.00) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL5996701 | 0.96 | HMGCR (0.93) | HMGCR | |
| SCHEMBL5224248 | 0.94 | HMGCR (0.88) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL5223752 | 0.94 | HMGCR (0.88) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL5329253 | 0.93 | HMGCR (0.87) | HMGCR | |
| SCHEMBL5991667 | 0.93 | HMGCR (0.87) | HMGCR | |
| SCHEMBL6418791 | 0.93 | HMGCR (0.87) | HMGCR | |
| SCHEMBL5994456 | 0.92 | HMGCR (0.85) | HMGCRNR1I2ABCB11RHOCCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008059372-A2 | CRYSTAL FORM OF (3R,5R)-7-[2-(4-FLUORO-PHENYL)-4-ISOPROPYL-5-(4-METYL-BENZYLCARBAMOYL)-2H-PYRAZOL-3-YL]-3,5-DIHYDROXY-HEPTANOIC ACID SODIUM SALT | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007049121-A1 | CRYSTAL FORM OF SODIUM; (3R,5R)-7-[4-BENZYLCARBAMOYL-2-(4-FLUOROPHENYL)-5-ISOPROPYL-IMIDAZOL-1-YL]-3,5-DIHYDROXY-HEPTANOATE | PFIZER PRODUCTS INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060287378-A1 | Novel pyrroles and imidazoles | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287378-A1 | Novel pyrroles and imidazoles | PPIP5K2, PPIE, PPOX | HMGCR 3534/4885NR1I2 3443/4885ABCB11 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.